The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1β-Secreting Cells
Abstract
Tumor cells secreting IL-1β are invasive and metastatic, more than the parental line or control mock-transfected cells, and concomitantly induce in mice general immune suppression of T cell responses. Suppression strongly correlates with accumulation in the peripheral blood and spleen of CD11b+/Gr-1+ immature myeloid cells and hematological alterations, such as splenomegaly, leukocytosis, and anemia. Resection of large tumors of IL-1β-secreting cells restored immune reactivity and hematological alterations within 7–10 days. Treatment of tumor-bearing mice with the physiological inhibitor of IL-1, the IL-1R antagonist, reduced tumor growth and attenuated the hematological alterations. Depletion of CD11b+/Gr-1+ immature myeloid cells from splenocytes of tumor-bearing mice abrogated suppression. Despite tumor-mediated suppression, resection of large tumors of IL-1β-secreting cells, followed by a challenge with the wild-type parental cells, induced resistance in mice; protection was not observed in mice bearing tumors of mock-transfected fibrosarcoma cells. Altogether, we show in this study that tumor-derived IL-1β, in addition to its proinflammatory effects on tumor invasiveness, induces in the host hematological alterations and tumor-mediated suppression. Furthermore, the antitumor effectiveness of the IL-1R antagonist was also shown to encompass restoration of hematological alterations, in addition to its favorable effects on tumor invasiveness and angiogenesis that have previously been described by us.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
Self-citationMechanisms and functional significance of tumour-induced dendritic-cell defects
Gabrilovich, D. (2004) · Nature Reviews Immunology · doi:10.1038/nri1498 · Cited by 1,024
IL-1 is required for tumor invasiveness and angiogenesis
Voronov, E., Shouval, D. S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., Dinarello, C. A., & Apte, R. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437939100 · Cited by 1,023
Self-citationMechanisms of suppression by suppressor T cells
von Boehmer, H. (2005) · Nature Immunology · doi:10.1038/ni1180 · Cited by 1,007
Going both ways: Immune regulation via CD1d-dependent NKT cells
Godfrey, D. I., & Kronenberg, M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200423594 · Cited by 877
Kusmartsev, S., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.989 · Cited by 850
The balance between IL-1 and IL-1Ra in disease
Arend, W. P. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00020-5 · Cited by 721
Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism
Mazzoni, A., Bronte, V., Visintin, A., Spitzer, J. H., Apolloni, E., Serafini, P., Zanovello, P., & Segal, D. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.2.689 · Cited by 690
The IL-1 family and inflammatory diseases.
Dinarello, C. A. (2002) · PubMed · Cited by 599
Self-citationζ Phosphorylation Without ZAP-70 Activation Induced by TCR Antagonists or Partial Agonists
Madrenas, J., Wange, R. L., Wang, J. L., Isakov, N., Samelson, L. E., & Germain, R. N. (1995) · Science · doi:10.1126/science.7824949 · Cited by 505
Cited by
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Neutrophils in cancer: Neutral no more
Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.52 · Cited by 1,830
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,447
Helicobacter pylori and Gastric Cancer: Factors That Modulate Disease Risk
Wroblewski, L. E., Peek, R. M., & Wilson, K. T. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00011-10 · Cited by 1,442
Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., & Van Ginderachter, J. A. (2008) · Blood · doi:10.1182/blood-2007-07-099226 · Cited by 1,234
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148
Bayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947
“…implicated in MDSC pathophysi- ology such that fibrosarcoma or 4T1 mammary carcinoma cell lines engineered to secrete IL-1b grow more rapidly than control tumors upon implantation due to enhanced accumulation of Gr-1+ CD11b+ and concomitant T cell suppression (Bunt et al., 2006; Song et al., 2005).”
BackgroundSinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M., & Ostrand-Rosenberg, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.977 · Cited by 847
Tu, S., Bhagat, G., Cui, G., Takaishi, S., Kurt-Jones, E. A., Rickman, B., Betz, K. S., Penz-Oesterreicher, M., Bjorkdahl, O., Fox, J. G., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.011 · Cited by 813
Self-citationShechter, R., London, A., Varol, C., Raposo, C., Cusimano, M., Yovel, G., Rolls, A., Mack, M., Pluchino, S., Martino, G., et al. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000113 · Cited by 770
Prostaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells
Sinha, P., Clements, V. K., Fulton, A. M., & Ostrand-Rosenberg, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4174 · Cited by 755
Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells
Sinha, P., Okoro, C., Foell, D., Freeze, H. H., Ostrand-Rosenberg, S., & Srikrishna, G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4666 · Cited by 725
Diverging inflammasome signals in tumorigenesis and potential targeting
Karki, R., & Kanneganti, T.-D. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0123-y · Cited by 641
Bunt, S. K., Yang, L., Sinha, P., Clements, V. K., Leips, J., & Ostrand-Rosenberg, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2354 · Cited by 633
Inflammasomes in carcinogenesis and anticancer immune responses
Zitvogel, L., Kepp, O., Galluzzi, L., & Kroemer, G. (2012) · Nature Immunology · doi:10.1038/ni.2224 · Cited by 593
The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions
Apte, R. N., Dotan, S., Elkabets, M., White, M. R., Reich, E., Carmi, Y., Song, X., Dvozkin, T., Krelin, Y., & Voronov, E. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9004-4 · Cited by 593
Self-citationOstrand-Rosenberg, S., Sinha, P., Beury, D. W., & Clements, V. K. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.01.011 · Cited by 583
Alshetaiwi, H., Pervolarakis, N., McIntyre, L. L., Ma, D., Nguyen, Q., Rath, J. A., Nee, K., Hernandez, G., Evans, K., Torosian, L., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aay6017 · Cited by 537
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity
Ostrand-Rosenberg, S. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0855-8 · Cited by 521
Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis
Wellenstein, M. D., Coffelt, S. B., Duits, D. E. M., van Miltenburg, M. H., Slagter, M., de Rink, I., Henneman, L., Kas, S. M., Prekovic, S., Hau, C.-S., et al. (2019) · Nature · doi:10.1038/s41586-019-1450-6 · Cited by 500
Ostrand-Rosenberg, S., & Fenselau, C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701019 · Cited by 509
Myeloid-Derived Suppressor Cells
(2015) · Advances in Cancer Research · doi:10.1016/bs.acr.2015.04.002 · Cited by 482
Immune surveillance: a balance between protumor and antitumor immunity
Ostrand-Rosenberg, S. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2007.12.007 · Cited by 480
Kaplanov, I., Carmi, Y., Kornetsky, R., Shemesh, A., Shurin, G. V., Shurin, M. R., Dinarello, C. A., Voronov, E., & Apte, R. N. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812266115 · Cited by 445
Self-citationSchlecker, E., Stojanovic, A., Eisen, C., Quack, C., Falk, C. S., Umansky, V., & Cerwenka, A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201018 · Cited by 438
Tumor exosomes inhibit differentiation of bone marrow dendritic cells
Yu, S., Liu, C., Su, K., Wang, J., Liu, Y., Zhang, L., Li, C., Cong, Y., Kimberly, R., Grizzle, W. E., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.6867 · Cited by 425
Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4+ and CD8+ T Cells
Hanson, E. M., Clements, V. K., Sinha, P., Ilkovitch, D., & Ostrand-Rosenberg, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804253 · Cited by 427
TNF signaling drives myeloid-derived suppressor cell accumulation
Zhao, X., Rong, L., Zhao, X., Li, X., Liu, X., Deng, J., Wu, H., Xu, X., Erben, U., Wu, P., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64115 · Cited by 378
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., Tian, Y., Niu, X., Wang, Y., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 373
Van Ginderachter, J. A., Movahedi, K., Hassanzadeh Ghassabeh, G., Meerschaut, S., Beschin, A., Raes, G., & De Baetselier, P. (2006) · Immunobiology · doi:10.1016/j.imbio.2006.06.002 · Cited by 371
Rébé, C., & Ghiringhelli, F. (2020) · Cancers · doi:10.3390/cancers12071791 · Cited by 337
Marciscano, A. E., Ghasemzadeh, A., Nirschl, T. R., Theodros, D., Kochel, C. M., Francica, B. J., Muroyama, Y., Anders, R. A., Sharabi, A. B., Velarde, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3427 · Cited by 335
Function and regulation of IL‐1α in inflammatory diseases and cancer
Malik, A., & Kanneganti, T. (2018) · Immunological Reviews · doi:10.1111/imr.12615 · Cited by 327
IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
Smith, C., Chang, M. Y., Parker, K. H., Beury, D. W., DuHadaway, J. B., Flick, H. E., Boulden, J., Sutanto-Ward, E., Soler, A. P., Laury-Kleintop, L. D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0014 · Cited by 322
Elkabets, M., Ribeiro, V. S. G., Dinarello, C. A., Ostrand‐Rosenberg, S., Di Santo, J. P., Apte, R. N., & Vosshenrich, C. A. J. (2010) · European Journal of Immunology · doi:10.1002/eji.201041037 · Cited by 319
Self-citationMyeloid-Derived Suppressor Cells in Inflammatory Bowel Disease: A New Immunoregulatory Pathway
Haile, L. A., von Wasielewski, R., Gamrekelashvili, J., Krüger, C., Bachmann, O., Westendorf, A. M., Buer, J., Liblau, R., Manns, M. P., Korangy, F., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.032 · Cited by 311
Sade-Feldman, M., Kanterman, J., Ish-Shalom, E., Elnekave, M., Horwitz, E., & Baniyash, M. (2013) · Immunity · doi:10.1016/j.immuni.2013.02.007 · Cited by 307
Okamoto, M., Liu, W., Luo, Y., Tanaka, A., Cai, X., Norris, D. A., Dinarello, C. A., & Fujita, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.064907 · Cited by 293
Self-citationTumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies
Cervantes-Villagrana, R. D., Albores-García, D., Cervantes-Villagrana, A. R., & García-Acevez, S. J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0205-z · Cited by 290
Krelin, Y., Voronov, E., Dotan, S., Elkabets, M., Reich, E., Fogel, M., Huszar, M., Iwakura, Y., Segal, S., Dinarello, C. A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2956 · Cited by 285
Self-citationTim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells
Dardalhon, V., Anderson, A. C., Karman, J., Apetoh, L., Chandwaskar, R., Lee, D. H., Cornejo, M., Nishi, N., Yamauchi, A., Quintana, F. J., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903275 · Cited by 278
Why not treat human cancer with interleukin-1 blockade?
Dinarello, C. A. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9229-0 · Cited by 277
Self-citationShifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
Quezada, S. A., Peggs, K. S., Simpson, T. R., & Allison, J. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01007.x · Cited by 276
Inflammation, inflammatory cells and angiogenesis: decisions and indecisions
Noonan, D. M., De Lerma Barbaro, A., Vannini, N., Mortara, L., & Albini, A. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9108-5 · Cited by 253
The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis
Carmi, Y., Voronov, E., Dotan, S., Lahat, N., Rahat, M. A., Fogel, M., Huszar, M., White, M. R., Dinarello, C. A., & Apte, R. N. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901511 · Cited by 224
Self-citationZhong, Z., Carroll, K. D., Policarpio, D., Osborn, C., Gregory, M., Bassi, R., Jimenez, X., Prewett, M., Liebisch, G., Persaud, K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1634 · Cited by 123
Engler, H., Bailey, M. T., Engler, A., Stiner-Jones, L. M., Quan, N., & Sheridan, J. F. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2007.10.007 · Cited by 97
MicroRNA-146a disrupts hematopoietic differentiation and survival
Starczynowski, D. T., Kuchenbauer, F., Wegrzyn, J., Rouhi, A., Petriv, O., Hansen, C. L., Humphries, R. K., & Karsan, A. (2011) · Experimental Hematology · doi:10.1016/j.exphem.2010.09.011 · Cited by 84
Maenhout, S. K., Thielemans, K., & Aerts, J. L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.956579 · Cited by 74
Chronic Psychological Stress Induces the Accumulation of Myeloid-Derived Suppressor Cells in Mice
Jin, J., Wang, X., Wang, Q., Guo, X., Cao, J., Zhang, X., Zhu, T., Zhang, D., Wang, W., Wang, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074497 · Cited by 53
Host effects contributing to cancer therapy resistance.
Katz, O. B., & Shaked, Y. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.12.002 · Cited by 47
IL-22 Signaling in the Tumor Microenvironment
Jiang, R., & Sun, B. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-55617-4_5 · Cited by 35
Metadata
- Authors
- Song, X., Krelin, Y., Dvorkin, T., Bjorkdahl, O., Segal, S., Dinarello, C. A., Voronov, E., & Apte, R. N.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-12
- Volume
- 175
- Issue
- 12
- Pages
- 8200-8208
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2126889178
- Cited by
- 290
- References
- 45
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.